1
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Protein C-Terminal Tyrosine Conjugation via Recyclable Immobilized BmTYR

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Protein modification plays an essential role in biological and pharmaceutical research. Due to the ordinary selectivity and inevitable damage to proteins of chemical synthetic methods, increased efforts were focused on biocatalysts which exhibited high regioselectivity and mild reaction conditions. However, separation of the biocatalysts and modified proteins remained a problem, especially when scaling up. Here, we developed a simple method for site-specific protein modification with a recyclable biocatalyst. The immobilizing tyrosinase (BmTYR) on magnetic beads can oxidize C-terminal tyrosine residues of the target protein to o-quinone, followed by the spontaneous addition of different nucleophiles (e.g., aniline derivatives), resulting in a C-terminal modified protein. Compared to the homogeneous biocatalytic system reported before, this heterogeneous system leads to an easier separation. Furthermore, the solid-phase biocatalyst can be regenerated during separation, providing reusability and lower costs.

          Related collections

          Most cited references41

          • Record: found
          • Abstract: not found
          • Article: not found

          Click Chemistry: Diverse Chemical Function from a Few Good Reactions

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Trypsin cleaves exclusively C-terminal to arginine and lysine residues.

            Almost all large-scale projects in mass spectrometry-based proteomics use trypsin to convert protein mixtures into more readily analyzable peptide populations. When searching peptide fragmentation spectra against sequence databases, potentially matching peptide sequences can be required to conform to tryptic specificity, namely, cleavage exclusively C-terminal to arginine or lysine. In many published reports, however, significant numbers of proteins are identified by non-tryptic peptides. Here we use the sub-parts per million mass accuracy of a new ion trap Fourier transform mass spectrometer to achieve more than a 100-fold increased confidence in peptide identification compared with typical ion trap experiments and show that trypsin cleaves solely C-terminal to arginine and lysine. We find that non-tryptic peptides occur only as the C-terminal peptides of proteins and as breakup products of fully tryptic peptides N-terminal to an internal proline. Simulating lower mass accuracy led to a large number of proteins erroneously identified with non-tryptic peptide hits. Our results indicate that such peptide hits in previous studies should be re-examined and that peptide identification should be based on strict trypsin specificity.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index.

              Antibody-drug conjugates enhance the antitumor effects of antibodies and reduce adverse systemic effects of potent cytotoxic drugs. However, conventional drug conjugation strategies yield heterogenous conjugates with relatively narrow therapeutic index (maximum tolerated dose/curative dose). Using leads from our previously described phage display-based method to predict suitable conjugation sites, we engineered cysteine substitutions at positions on light and heavy chains that provide reactive thiol groups and do not perturb immunoglobulin folding and assembly, or alter antigen binding. When conjugated to monomethyl auristatin E, an antibody against the ovarian cancer antigen MUC16 is as efficacious as a conventional conjugate in mouse xenograft models. Moreover, it is tolerated at higher doses in rats and cynomolgus monkeys than the same conjugate prepared by conventional approaches. The favorable in vivo properties of the near-homogenous composition of this conjugate suggest that our strategy offers a general approach to retaining the antitumor efficacy of antibody-drug conjugates, while minimizing their systemic toxicity.
                Bookmark

                Author and article information

                Journal
                ACS Omega
                ACS Omega
                ao
                acsodf
                ACS Omega
                American Chemical Society
                2470-1343
                31 October 2022
                08 November 2022
                : 7
                : 44
                : 40532-40539
                Affiliations
                []State Key Laboratory of Drug Research, Shanghai Institute of Materia, Medica, Chinese Academy of Sciences , Shanghai 201203, China
                []Shanghai Institute of Materia Medica, Chinese Academy of Sciences , Shanghai 201203, China
                [§ ]School of Pharmaceutical Science and Technology, Hangzhou Institute for Advanced Study , Hangzhou 310024, China
                []University of Chinese Academy of Sciences , Beijing 100049, China
                Author notes
                Author information
                https://orcid.org/0000-0002-8167-9750
                https://orcid.org/0000-0003-1770-6272
                Article
                10.1021/acsomega.2c05794
                9647846
                36385814
                47397732-2f4c-4417-832f-888a49729f8e
                © 2022 The Authors. Published by American Chemical Society

                Permits non-commercial access and re-use, provided that author attribution and integrity are maintained; but does not permit creation of adaptations or other derivative works ( https://creativecommons.org/licenses/by-nc-nd/4.0/).

                History
                : 06 September 2022
                : 19 October 2022
                Categories
                Article
                Custom metadata
                ao2c05794
                ao2c05794

                Comments

                Comment on this article